RxDoctor Payments Data

Katharine Decena, MD

Cardiovascular Disease · Norwich, CTNPI 1962715169

Payments from drug & device makers

$1,510in general payments, 2019–2025

Across 56 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$231
  • Abbott$229
  • E.r. Squibb & Sons, L.L.C.$202
  • Astellas Pharma US Inc$160
  • Novartis$143
  • Amgen$138
  • plus $407 from 10 others

What the payments were for

  • Food & beverage$1,32888%
  • Education$18212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,510 in reported general payments places this provider in the 50th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$125,019
Medicare patients
1,368
Services billed
2,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban652$845,203
XareltoRivaroxaban172$196,078
JardianceEmpagliflozin128$165,589
EntrestoSacubitril/Valsartan91$142,408
Repatha SureclickEvolocumab34$25,300
FarxigaDapagliflozin Propanediol29$23,728
NexletolBempedoic Acid19$18,982
BrilintaTicagrelor18$16,024
VascepaIcosapent Ethyl31$13,791
Metoprolol Succinate649$8,650
Dofetilide13$7,094
CorlanorIvabradine Hcl12$6,370
Atorvastatin Calcium638$5,248
Carvedilol501$4,303
Rosuvastatin Calcium310$3,804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$100$845,203652 claims
Johnson & JohnsonXarelto$231$196,078172 claims
Boehringer IngelheimJardiance$19$165,589128 claims
NovartisEntresto$143$142,40891 claims
AmgenCorlanor$138$6,37012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →